William D. McClellan Jr. - 08 Jun 2022 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Director
Signature
/s/ Tracy Herson, attorney-in-fact
Issuer symbol
RETA
Transactions as of
08 Jun 2022
Transactions value $
$154,942
Form type
4
Filing time
09 Jun 2022, 16:37:14 UTC
Previous filing
05 Jan 2022
Next filing
16 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $9.98K +287 +486.44% $34.76* 346 08 Jun 2022 Direct F1, F2
transaction RETA Class A common stock Award $135K +3.88K +1122.25% $34.76* 4.23K 08 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right-to-buy) Award $9.99K +416 $24.02* 416 08 Jun 2022 Class A common stock 416 $34.76 Direct F3, F4
transaction RETA Stock Option (right-to-buy) Award $0 +5.62K $0.00 5.62K 08 Jun 2022 Class A common stock 5.62K $34.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units (RSU), which vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date.
F2 These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $10,000.00.
F3 The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date.
F4 These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $10,000.00.